Lyell Immunopharma, Inc. (LYEL) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 27.00K USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $27.00K | (m) | (m) |
| 2026-03-31 | (m) | $31.00K | (m) | (m) |
| 2025-12-31 | (m) | $36.00K | (m) | (m) |
| 2025-09-30 | (m) | $41.00K | (m) | (m) |
| 2025-06-30 | (m) | $60.00K | (m) | (m) |
| 2025-03-31 | (m) | $65.00K | (m) | (m) |
| 2024-12-31 | (m) | $61.00K | (m) | (m) |
| 2024-09-30 | (m) | $63.00K | (m) | (m) |
| 2024-06-30 | (m) | $54.00K | (m) | (m) |
| 2024-03-31 | (m) | $68.00K | (m) | (m) |
| 2023-12-31 | (m) | $130.00K | (m) | (m) |
| 2023-09-30 | (m) | $48.50M | (m) | (m) |
| 2023-06-30 | (m) | $48.48M | (m) | (m) |
| 2023-03-31 | (m) | $84.19M | (m) | (m) |
| 2022-12-31 | (m) | $84.68M | (m) | (m) |
| 2022-09-30 | (m) | $39.12M | (m) | (m) |
| 2022-06-30 | (m) | $41.87M | (m) | (m) |
| 2022-03-31 | (m) | $8.76M | (m) | (m) |
| 2021-12-31 | (m) | $10.65M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $7.76M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $657.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |